



CCHPBC Board Meeting

Thursday, June 19, 2025
11:30 a.m. - 3:00 p.m.
By Zoom videoconference

Attendance:

Board Members:	Allan Seckel, Board Chair Christopher Anderson Kelly Fujibayashi Elliot Mayhew Jonathan Norton Harman Pandher Jocelyn Stanton Jacqueline Tarantino Asa Tooshkenig Jason Tutt
Regrets:	Benjamin Campbell Terri Van Steinburg
Staff:	Carin Plischke, Registrar & CEO Kate Parisotto, Chief Regulatory Officer Dr Michelle Payne, Practice Advisor Doug Wright, Director, Quality Assurance and Practice Sandy Marji, Executive Assistant
Recording Secretary:	Jessica Gruchey, Raincoast Ventures Ltd.
Virtual Meeting Host	Patricia Bentley, Charest Legal Solutions



1. Call to Order

The College of Complementary Health Professionals of BC (CCHPBC) Board meeting was called to order at 11:38 a.m.

2. Territorial Land Acknowledgement

Chair Allan Seckel welcomed members to the virtual meeting. Gratitude was extended to the First Nations of the lands from which members were participating, and it was acknowledged that the CCHPBC Office is located on the unceded lands of the xʷməθ kʷəy̓əm (Musqueam), Skwxwú7mesh (Squamish), and səliłwətał (Tsleil-Waututh) Nations.

3. Opening Remarks

Chair Allan Seckel provided a brief introduction.

4. Approval of Agenda

Materials:

- *Agenda for the CCHPBC Board Meeting scheduled June 19, 2025*

The June 19, 2025, CCHPBC Board Meeting agenda was presented for adoption.

MOVED By Chris Anderson

THAT the June 19, 2025, College of Complementary Health Professionals of British Columbia Board Meeting agenda be approved.

CARRIED

5. Approval of Minutes

Materials:

- *Minutes of the CCHPBC Board Meeting held March 31, 2025*

The March 31, 2025, CCHPBC Board Meeting Minutes were presented for adoption.

MOVED By Jacqueline Tarantino

THAT the March 31, 2025, College of Complementary Health Professionals of British Columbia Board Meeting Minutes be approved.

CARRIED

6. Registrar's Report

Materials:

- *Registrar's Report*

Carin Plischke, Registrar and CEO, referenced the distributed Registrar's Report.



7. Regulatory Update

Materials:

- *Regulatory Committees – Briefing Note*
- *Inquiry & Discipline Report to the Board – Briefing Note*
- *Quality Assurance & Practice Report to the Board – Briefing Note*
- *Licensure Report to the Board – Briefing Note*

Kate Parisotto, Chief Regulatory Officer, referenced the distributed Briefing Note, and discussion ensued.

8. ND Prescription Standard

Dr Michelle Payne, Practice Advisor, and Doug Wright, Director, Quality Assurance and Practice, joined the meeting (11:59 a.m.).

Materials:

- *New & Missing Drugs – Briefing Note*

With the aid of a PowerPoint presentation, Michelle Payne, Practice Advisor, provided background information on how naturopathic medicine is regulated by the CCHPBC and discussed the New Drug Review Process.

MOVED By Jacqueline Tarantino

THAT the CCHPBC MOVE to approve to exclude the following drugs in the limits and conditions of the Scope of Practice for Naturopathic Physicians: Standards, Limits and Conditions for Prescribing, Dispensing and Compounding Drugs:

Afatinib or its salts	Fluralaner	Ponatinib or its salts
Aflibercept	Fostemsavir or its salts	Ponesimod
Afoxolaner	Gamithromycin	Pradofloxacin or their salts or derivatives
Agalsidase Beta	Glofitamab	Ramucirumab
Alglucosidase alfa	Grazoprevir	Riociguat or its derivatives
Alpha1- proteinase inhibitor (human)	Guselkumab	Robenacoxib or its salts
Andexanet alfa	Ibafloxacin	Sacubitril or its salts



Anifrolumab	Ibogaine or its salts or derivatives or analogues	Sarilumab
Apremilast	Ibrutinib or its salts	Sebelipase alfa
Asfotase alfa	Icatibant or its salts	Secukinumab
Asparaginase (by injection)	Idebenone	Setmelanotide or its salts
Atezolizumab	Idelalisib	Sevoflurane
Avalglucosidase alfa	Idursulfase	Siltuximab
Avelumab	Imdevimab	Simeprevir or its salts
Avermectin or its derivatives	Imidapril or its salts	Sodium nitrite (When indicated for administration by injection and sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning.)
Avilamycin or its salts or derivatives	Ingenol mebutate or its derivatives	Sorafenib or its salts
Azacitidine or its salts or derivatives	Ledipasvir or its salts	Spesolimab
Belimumab	Lenvatinib or its salts	Talazoparib or its salts
Binimetinib or its salts	Letermovir or its salts	Taliglucerase alfa
Blinatumomab	Lifitegrast or its salts	Tecovirimat
Bosutinib or its salts	Lomitapide or its salts	Tedizolid or its salts or derivatives (parenteral only)
Brentuximab vedotin	Macitentan or its derivatives	Teduglutide
Brilliant Blue G or its derivatives	Maropitant or its salts	Telaprevir or its derivatives
Bromfenac or its salts	Mecasermin	Tepoxalin or its derivatives
Canakinumab	Melarsomine or its salts	Tesamorelin or its salts or derivatives



Carglumic acid or its salts or derivatives	Mepolizumab	Tezacaftor or its salts
Casirivimab	Midostaurin or its salts	Tigecycline
Ceritinib or its salts	Mitratapide	Toceranib or its salts
Certolizumab pegol	Natalizumab	Tocilizumab
Clevidipine or its salts	Necitumumab	Tofacitinib or its salts
Clofarabine	Nesiritide or its salts	Toltrazuril or its salts or derivatives (including Ponazuril)
Concizumab	Netupitant	Tolvaptan or its derivatives
Cysteamine (Mercaptamine) or its salts	Nintedanib or its salts	Triptorelin or its salts or derivatives
Daclatasvir or its salts	Nivolumab	Urokinase
Daclizumab beta	Nusinersen	Vedolizumab
Dasabuvir or its salts	Obinutuzumab	Velpatasvir
Defibrotide or its salts or derivatives	Oclacitinib or its salts	Vericiguat or its salts
Degarelix or its salts or derivatives	Ocrelizumab	Vernakalant or its salts
Dirlotapide	Ocriplasmin	Voxilaprevir or its salts
Dolutegravir or its salts	Olaratumab	Cytomegalovirus immune globulins
Dostarlimab	Ombitasvir	Hepatitis B immune globulin
Dupilumab	Paritaprevir (Veruprevir)	Immune globulin products
Durvalumab	Pasireotide or its salts	Rho D immune globulin
Eliglustat or its salts	Pazopanib or its salts	Rabies immune globulin
Elosulfase alfa	Pegaspargase	Tetanus immune globulin



Eltrombopag or its salts	Pembrolizumab	Varicella Zoster immune globulin
Emamectin or its salts	Peramivir or its salts or derivatives	
Encorafenib or its salts	Phenylbutyric acid or its salts or derivatives	
Eplerenone	Pibrentasvir	
Eribulin or its salts or derivatives	Plerixafor or its salts	
Etryptamine and its salts	Polidocanol (injection)	
Firocoxib	Pomalidomide or its salts	

THAT the CCHPBC further MOVE to approve to exclude the following drugs in the limits and conditions of the Scope of Practice for Naturopathic Physicians: Standards, Limits and Conditions for Prescribing, Dispensing and Compounding Drugs:

Iptacopan	Retifanlimab
Zolbetuximab	Rozanolixizumab
Efanesoctocog alfa	Sipavibart
Inavolisib or its salts	Tofersen
Loncastuximab tesirine	Vaborbactam

THAT the CCHPBC further MOVE to approve to apply conditions to the following drugs in the limits and conditions of the Scope of Practice for Naturopathic Physicians: Standards, Limits and Conditions for Prescribing, Dispensing and Compounding Drugs:

For continuation only:

Asenapine or its salts and derivatives	Brexpiprazole or its salts
Cariprazine or its salts	Cenobamate or its salts



Eslicarbazepine acetate

Lacosamide or its derivatives

Obeticholic acid or its salts

Bacillus Calmette-Guérin (BCG) (when
sold or recommended as an anti-
neoplastic agent)

For Health Canada Approved uses only:

Fecal Microbiota

For NDs holding certification in IV/Chelation Therapy only:

Deferiprone or its derivatives

Carried

9. ND Laboratory Services Requirement

Materials:

- *Laboratory and Diagnostic Testing Referrals - Briefing Note*

Michelle Payne referenced the distributed Briefing Note, and discussion ensued.

MOVED By Chris Anderson

THAT the CCHPBC amend the Practice Standard: Laboratory and Diagnostic Testing Referrals as indicated in Appendix 2 to this Briefing Note, effective July 15, 2025.

Carried

Dr. Michelle Payne and Doug Wright departed the meeting (12:28 p.m.).

10. Governance

Materials:

- *Governance Committee Update - Briefing Note*

Jocelyn Stanton referenced the distributed Briefing Note.

MOVED By Jocelyn Stanton

Inquiry Committee

THAT the Governance Committee, RECOMMEND to the Board that Pezhman PJ Azad, Martin Chia-Lung Ma, Christopher Gainor, Pamela Nonis, and Mona Kwong be reappointed as members of the Inquiry Committee for a term starting on July 1, 2025 and ending on June 30, 2026.

THAT the Governance Committee further RECOMMEND to the Board that Teresa Budd be



reappointed as Committee Chair and Brett Peters, Robin Perry, Rebecca Pitfield, Adrian Chaster, Lynne Harris, Nassim Baharian, and Richard Walker by reappointed as Committee Vice-Chairs for a term starting on July 1, 2025 and ending on June 30, 2026.

Registration Committee

THAT the Governance Committee RECOMMEND to the Board that Nadine Hawryluk, Kimiya Sabbaghan, and Hamid Tajbakhsh be reappointed as members of the Registration Committee for a term starting on July 1, 2025 and ending on June 30, 2026.

THAT the Governance Committee further RECOMMEND to the Board that Brad Matthews be reappointed as Committee Chair, and Misty Watson, Harris Fisher, Weijia Tan, Aisha Ohene-Asante, and Janice Penner be reappointed as Committee Vice-Chairs for a term starting on July 1, 2025 and ending on June 30, 2026.

Quality Assurance Committee

THAT the Governance Committee RECOMMEND to the Board that Tasreen Alibhai, Eyal Lebel, Leif Sigurdson, Laura Dunkley, Karen McGee, Aitan Goldshmidt, and Ben Cao be reappointed as members of the Quality Assurance Committee for a term starting on July 1, 2025 and ending on June 30, 2026.

THAT the Governance Committee further RECOMMEND to the Board that Marilynne Waithman be reappointed as Committee Chair, and Johnny Suchdev, Gaetano Morello, and Catherine Cameron be reappointed as Committee Vice-Chairs for a term starting on July 1, 2025 and ending on June 30, 2026.

Discipline Committee

THAT the Governance Committee RECOMMEND to the Board that Jacqueline Chan, Jenelle Hynes, Doug Steventon, Misty Watson, and Christopher Spooner be reappointed as members of the Discipline Committee for a term starting on July 1, 2025 and ending on June 30, 2026.

THAT the Governance Committee further RECOMMEND to the Board that Carol Williams be reappointed as Committee Chair, and Howard Kushner and Roland Mitchell be reappointed as Committee Vice-Chairs for a term starting on July 1, 2025 and ending on June 30, 2026.

Professional Practice and Standards Advisory Committee

THAT the Governance Committee RECOMMEND to the Board that Nadine Hawryluk, Ashleigh Lane, Xiaoning (Jeffrey) Liu, Karen Parmar, Kelvin Bei, and Eyal Lebel be reappointed as members of the Professional Practice and Standards Advisory Committee for a term starting on July 1, 2025 and ending on June 30, 2026.

Carried

11. Next Meeting Date

The Chair advised that the next meeting will be held on October 17, 2025, in person at the



CCHPBC Office, located at 900 Granville Street, Vancouver, BC. Additionally, a brief virtual meeting will be held in September 2025, date to be determined.

12. Closing

The meeting adjourned to an in-camera meeting at 12:35 p.m.